HC Wainwright restated their buy rating on shares of Sernova (TSE:SVA – Get Rating) in a research note published on Friday morning, Stock Target Advisor reports. The brokerage currently has a C$6.00 price objective on the stock. HC Wainwright also issued estimates for Sernova’s FY2027 earnings at $0.17 EPS.
Separately, Roth Capital reaffirmed a buy rating on shares of Sernova in a research note on Tuesday, September 20th.
Sernova Stock Performance
Shares of SVA stock opened at C$0.81 on Friday. Sernova has a 1 year low of C$0.69 and a 1 year high of C$2.22. The firm has a market cap of C$237.43 million and a price-to-earnings ratio of -19.29. The stock’s fifty day simple moving average is C$0.86. The company has a quick ratio of 18.11, a current ratio of 18.26 and a debt-to-equity ratio of 0.73.
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for Sernova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sernova and related companies with MarketBeat.com's FREE daily email newsletter.